Stereotaxis Inc. logo

Stereotaxis Inc. (RJR1)

Market Closed
12 Dec, 20:00
XFRA XFRA
2. 02
+0.05
+2.54%
- Market Cap
- P/E Ratio
0% Div Yield
1,970 Volume
-0.23 Eps
1.97
Previous Close
Day Range
2.02 2.02
Year Range
1.39 3
Want to track RJR1 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 75 days

Summary

RJR1 closed yesterday higher at €2.02, an increase of 2.54% from Thursday's close, completing a monthly decrease of -0.98% or €0.02. Over the past 12 months, RJR1 stock lost -7.34%.
RJR1 is not paying dividends to its shareholders.
The last earnings report, released on Nov 11, 2025, missed the consensus estimates by -0.01%. On average, the company has surpassed earnings expectations by 0.02%, based on the last three reports. The next scheduled earnings report is due on Feb 27, 2026.
Stereotaxis Inc. has completed 2 stock splits, with the recent split occurring on Nov 04, 2013.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on AMEX (USD).

RJR1 Chart

STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics

STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics

Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.

Zacks | 1 month ago
Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript

Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript

Stereotaxis, Inc. ( STXS ) Q3 2025 Earnings Call November 11, 2025 4:30 PM EST Company Participants David Fischel - CEO & Chairman Kimberly Peery - Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen, Research Division Adam Maeder - Piper Sandler & Co., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good afternoon. Thank you for joining us for Stereotaxis' Third Quarter 2025 Earnings Conference Call.

Seekingalpha | 1 month ago
Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates

Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.08 per share a year ago.

Zacks | 1 month ago

Stereotaxis Inc. (RJR1) FAQ

What is the stock price today?

The current price is €2.02.

On which exchange is it traded?

Stereotaxis Inc. is listed on AMEX.

What is its stock symbol?

The ticker symbol is RJR1.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Feb 27, 2026.

Has Stereotaxis Inc. ever had a stock split?

Stereotaxis Inc. had 2 splits and the recent split was on Nov 04, 2013.

Stereotaxis Inc. Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
David Leo Fischel C.A.I.A., CEO
XFRA Exchange
US85916J4094 ISIN
US Country
139 Employees
- Last Dividend
4 Nov 2013 Last Split
12 Aug 2004 IPO Date

Overview

Stereotaxis, Inc. is a pioneering company in the field of robotic systems, specializing in the design, manufacture, and marketing of advanced robotics, instruments, and information systems geared towards the interventional laboratory sector. Operating both in the United States and internationally, the company's cutting-edge technology primarily serves the purpose of enhancing the precision and safety of complex interventional procedures. Through its innovative solutions, Stereotaxis aims to facilitate physicians in navigating and manipulating devices within the human body with an unprecedented level of control and accuracy. Founded in 1990 and headquartered in Saint Louis, Missouri, Stereotaxis has established a strong reputation for its contribution to minimally invasive medical procedures, particularly in the realm of cardiology. The company’s commitment to innovation is also reflected in its strategic collaborations, such as with MAGiC catheter for cardiac ablation procedures, further emphasizing its role in advancing medical technology.

Products and Services

  • Robotic Magnetic Navigation (RMN) Systems – Including the Genesis RMN and Niobe systems, these platforms represent the core of Stereotaxis' offerings. They facilitate the image-guided delivery of catheters and guidewires through blood vessels and heart chambers directly to the sites requiring treatment, enabling physicians to perform complex interventional procedures with enhanced precision and safety.
  • Odyssey Information Solution – This comprehensive solution empowers hospitals and clinics to manage, control, record, and share interventional procedures in real-time across networks. The Odyssey platform is designed to streamline procedural workflows and enhance collaboration among medical professionals, irrespective of their physical location.
  • Stereotaxis Imaging Model S X-Ray System – As part of its offering for a fully robotic interventional operating room, this single-plane, full-power x-ray system includes a c-arm, powered table, motorized boom, and monitors. It's optimized to work seamlessly with Stereotaxis’ robotic systems, providing clear and precise imaging during procedures.
  • Disposables and Accessories – Among these, QuikCAS automated catheter advancement disposables stand out for their capability to advance electrophysiology catheters remotely, enhancing the efficiency and safety of cardiac interventions.
  • Vdrive System – This system enhances the navigation and stability of diagnostic and therapeutic devices during interventional procedures. By improving the control over these devices, Vdrive contributes to the overall precision and success of interventions.
  • V-Loop, V-Sono, and V-CAS Disposables – These components are designed to work with the Vdrive system, providing specific functionalities such as loop creation, ultrasound navigation, and catheter stability during interventional procedures. Each is developed to alleviate common challenges faced during complex medical interventions, thereby improving outcomes and patient safety.

Contact Information

Address: 710 North Tucker Boulevard
Phone: 314 678 6100